EcN-TNFaNb and EcN-IL10 demonstrated effective mitigation of DSS-induced mouse colitis, as indicated by reduced colon length shortening, lower disease activity index (DAI), and altered expression of pro-inflammatory cytokines in colon tissues, such as TNF-α, IL-6, IL-17 A, and MCP-1. Here, IL10 is linked to colitis.